Arlington, Massachusetts, USA, November 18, 2026
Eloxx Pharmaceuticals, Inc. has announced the publication of Phase 2a clinical data evaluating its investigational drug candidate exaluren (formerly ELX-02) in patients with nonsense mutation Alport syndrome in the Journal of Clinical Investigation (JCI). The findings provide first-in-human evidence that exaluren may promote the production of collagen IV in kidney cells affected by genetic mutations. In the small, open-label proof-of-mechanism study, kidney biopsy assessments showed increased collagen IV protein abundance and partially improved podocyte morphology in all three participants following treatment. The results offer an important scientific basis for further investigation of this targeted approach to inherited kidney disease. Eloxx is continuing the clinical development programme through its Phase 2b EXACT study, which is designed to evaluate exaluren in a larger patient population using a randomized, placebo-controlled trial design.
Phase 2a Study Shows Changes in Kidney Biomarkers
The Phase 2a study enrolled three adolescents aged 12 to 18 years with autosomal recessive Alport syndrome associated with a premature termination codon in the COL4A4 gene. Participants received daily subcutaneous exaluren at a dose of 0.75 mg/kg for eight weeks. The primary objective was to assess the drug’s safety and tolerability, while secondary assessments included kidney biopsies conducted before and after treatment. The published findings showed increased levels of collagen α3(IV), α4(IV) and α5(IV) in kidney tissue across all three participants. Researchers also reported more physiologically localized collagen α5(IV) and partially improved podocyte morphology. A masked machine-learning analysis of electron microscopy images identified reductions in podocyte foot process width of 46%, 14% and 16% in the three participants, respectively. Exploratory assessments also indicated increased filtration slit density in all participants, with the mean density rising by approximately 50% and reaching more than 80% of healthy control values. These observations are relevant because podocytes are specialised kidney cells that help maintain the filtration barrier. Damage to their structure can contribute to protein leakage and progressive kidney dysfunction. However, the study was very small and designed primarily to investigate biological activity, meaning the findings require confirmation in larger clinical trials.
Exaluren Uses a Targeted Readthrough Mechanism
Alport syndrome is an inherited kidney disorder caused by mutations in the COL4A3, COL4A4 or COL4A5 genes, which encode components of the collagen IV network in the glomerular basement membrane. This network plays an essential role in maintaining the kidney’s filtration structure. In patients with nonsense mutations, an abnormal premature stop signal can interrupt protein production, preventing cells from producing full-length functional collagen IV. These mutations are associated with progressive kidney damage and an increased risk of kidney failure, sometimes during early adulthood. Exaluren is an investigational ribosome-targeting glycoside designed to promote readthrough of premature stop codons without interfering with normal stop signals. By encouraging the cellular protein-production machinery to bypass the abnormal signal, the treatment aims to enable the production of full-length proteins. The compound is designed to accumulate in kidney cells, making it a potential targeted approach for genetic kidney diseases involving nonsense mutations. The Phase 2a findings are particularly relevant because they provide human kidney tissue evidence consistent with the intended biological mechanism. Nevertheless, changes in proteinuria were inconsistent among participants, and hematuria persisted in all three patients. The researchers noted that the short treatment duration and variability within individual patients limited interpretation of these clinical measures. There are currently no approved treatments specifically for Alport syndrome.
Phase 2b EXACT Trial to Evaluate Further Evidence
The published results support Eloxx’s ongoing Phase 2b EXACT clinical study, a global, randomized, placebo-controlled, delayed-start trial designed to enrol approximately 24 patients with Alport syndrome caused by nonsense mutations in the COL4A3, COL4A4 or COL4A5 genes. The initial 16-week placebo-controlled portion is designed to evaluate changes in podocyte foot process effacement, measured through filtration slit density in kidney biopsy samples. The first participants were dosed in September 2026. Eloxx expects to report topline results from the initial placebo-controlled portion in mid-2027, followed by 32-week data by the end of 2027. Unlike the earlier Phase 2a study, the randomized design is intended to provide a more robust assessment of treatment-related changes. Exaluren is also being developed for other rare kidney diseases associated with nonsense mutations, including autosomal dominant polycystic kidney disease.
Safety findings from the Phase 2a study indicated that exaluren was generally well tolerated, with no serious adverse events, treatment discontinuations, nephrotoxicity or ototoxicity reported. Most adverse events were Grade 1 and resolved spontaneously. While these early findings are encouraging, the small participant population and limited treatment period mean that long-term safety and clinical benefit remain to be established. The ongoing EXACT study will be important in determining whether the biological changes observed in the initial research translate into meaningful benefits for people living with Alport syndrome.
Source: Eloxx Pharmaceuticals press release



